Currently, PUK is indicated for STEMI. STEMI is caused by continuous obstruction of blood supply, which may lead to large-scale necrosis of myocardial cells. The clinical manifestations are mainly chest pains and ST-segment elevation and dynamic evolution of ECG. Acute ST-segment elevation myocardial infarction is a life-threatening and time-sensitive acute disease. The patient must seek medical treatment in time and undergo coronary artery reperfusion therapy including PCI (percutaneous coronary intervention) or thrombolysis as soon as possible. PUK should be used in the thrombolytic treatment of STEMI.

Unlike Alteplase, the most commonly used thrombolytic drug in China, PUK does not form a covalent complex with protease inhibitors in plasma, which means the blood concentration of PUK and protease inhibitors will not decrease. This inhibitor is directly related to the prevention of systemic bleeding, for a higher inhibitor concentration is beneficial for reducing the rate of intracranial hemorrhage in patients.